Carregant...
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
BACKGROUND & AIMS: It is unclear if there are differences between direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in risk of hepatocellular carcinoma (HCC) after antiviral therapy. We aimed to compare different DAA regimens with respect to risk of de novo HCC following antiviral ther...
Guardat en:
| Publicat a: | Eur J Gastroenterol Hepatol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279503/ https://ncbi.nlm.nih.gov/pubmed/30142097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MEG.0000000000001242 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|